Genedrive PLC Director/PDMR Shareholding (2703V)
April 05 2019 - 2:29AM
UK Regulatory
TIDMGDR
RNS Number : 2703V
Genedrive PLC
05 April 2019
Notification and public disclosure of transactions by persons
discharging
managerial responsibilities and persons closely associated with
them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the
near patient molecular diagnostics company, announces that it has
granted share options ("Options") to members of its senior
management team to acquire a total of 1,330,000 ordinary shares of
1.5p each in the capital of the Company under the Company's Share
Option Scheme.
The Options have been granted with an exercise price equal to
the close price on the day before grant and vest after a period of
three years. The Options are exercisable over the period of 10
years from the date of grant.
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name David Budd CEO
Matthew Fowler CFO
Gino Miele R&D Director
Gordon Powell Commercial Director
Colleen Pythian Director of Quality & Regulation
Warren Berry Operations Director
------------------------------- -------------------------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------------------------
a. Position/status 1.
------------------------------- -------------------------------------------------------------
a. Initial notification Initial notification
/Amendment
------------------------------- -------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------
a. Name genedrive plc
------------------------------- -------------------------------------------------------------
b. LEI
213800ZYODIRZ87Y4K14
------------------------------- -------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------------------
a. Description of Options over ordinary shares of 1.5 pence
the each
Financial instrument,
type
of instrument
Identification
code
------------------------------- -------------------------------------------------------------
b. Nature of the Grant of options pursuant to and in accordance
transaction with the terms of the Company's Share Option
Scheme dated 29 November 2017.
------------------------------- -------------------------------------------------------------
c. Price(s) and Option price(s) Volume(s)
volume(s) David Budd 23.5p 540,000
---------------- ----------
Matthew Fowler 23.5p 340,000
---------------- ----------
Gino Miele 23.5p 150,000
---------------- ----------
Gordon Powell 23.5p 150,000
---------------- ----------
Colleen Pythian 23.5p 75,000
---------------- ----------
Warren Berry 23.5p 75,000
---------------- ----------
------------------------------- -------------------------------------------------------------
d. Aggregated information
* Aggregated volume N/A
* Price
------------------------------- -------------------------------------------------------------
e. Date of the transaction 2019-April-04; UTC time
------------------------------- -------------------------------------------------------------
f. Place of the Outside trading venue - shares to be admitted
transaction to AIM market of London Stock Exchange plc
on exercise of options
------------------------------- -------------------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP +44 (0)207 418 8900
James Steel / Oliver Jackson
Stanford Capital Partners Limited +44 (0) 20 3815 8880
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor +44 (0)20 7933 8780
Relations) or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAXLSEAPNEEF
(END) Dow Jones Newswires
April 05, 2019 03:29 ET (07:29 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024